Crinetics Pharmaceuticals 주식 (NASDAQ: CRNX)

에 대한 최신 뉴스 Crinetics Pharmaceuticals (NASDAQ:CRNX) 주식

CRINETICS PHARMACEUTICALS IN

Crinetics Pharmaceuticals

Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.

QuantumScape QS Stock

Equities

Mid Cap

News

Movers

General

APGE

CRNX

JOBY

KYMR

LNTH

PLUG

SMMT

XPEV

다음은 지난주 큰 폭의 상승세를 보인 11개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요? 퀀텀스케이프(NYSE:QS)의 주가는 회사가 폭스바겐(Volkswagen)의 배터리 회사인 파워코(PowerCo)와 전고체 배터리 산업화 계약을 체결했다고 발표한 후 64.34% 급등했다.

샤오펑 및 퀀텀스케이프는 지난주 최고 성과를 보여준 11개 중형주 중 일부(7월 7일-7월 13일)

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals Inc

With an ugly geopolitical flashpoint seemingly averted for now, Brazilian energy giant Petrobras (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBR#NYSE">PBR</a>) and other hydrocarbon specialists incurred some red ink during the midweek session. On Tuesday, President Donald Trump declared that a <a href="https://www.benzinga.com/markets/equities/25/06/46090358/us-stocks-likely-to-edge-higher-as-iran-israel-ceasefire-holds-micron-technology-general-mills-in-focus-ahead-of-earnings">ceasefire between Israel and Iran</a> was in effect, despite reports of renewed hostilities putting the deal into question. For now, the agreement seems to be holding. Still, the tenuous framework may eventually present a cynical upside opportunity for PBR stock.
On a Truth Social post, Trump stated that "Israel is not going to attack Iran. All planes will turn around and head home, while doing a friendly ‘Plane Wave' to Iran." Assuming that the ceasefire leads to a more sustained solution, the threat of global oil disruption has declined, thus leading to increasing pressure against PBR stock and its ilk.
Since Israel launched its attack against Iran on June 13, a key concern has been the Strait of Hormuz. A pivotal energy artery, the passage accounts for <a href="https://www.benzinga.com/etfs/sector-etfs/25/06/46056666/how-a-strait-of-hormuz-shock-could-ignite-a-surge-in-energy-and-defense-etfs">nearly one-third of the world's oil supply</a>. With the U.S. military launching B-2 bombers to <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46082397/oil-prices-tumble-as-israel-iran-ceasefire-takes-shape-for-now">strike multiple Iranian nuclear facilities</a>, tensions and anxieties skyrocketed.
Even with the ceasefire in effect, analysts remain cautious, pointing to the fragile nature of the agreement, along with the potential for renewed clashes. A major source of friction is the stated reason why Israel and the U.S. attacked Iran: the country's nuclear program.
According to a CBS News <a href="https://www.cbsnews.com/news/israel-iran-ceasefire-uncertainty-nuclear-program-strikes-iaea-monitoring/">report</a>, an initial classified intelligence assessment revealed that Iran's nuclear capability was only set back by months. What's more, Iranian Parliamentary Speaker Mohammad Bagher Qalibaf stated that the peaceful nuclear program will "move forward at a faster pace."
If so, a geopolitical cloud continues to hang over the region, which could potentially ignite oil prices.
<h2 class="wp-block-heading">Leveraging Statistics To Trade PBR Stock</h2>
Although the concept of the energy market swinging back to life following another unexpected event may be enticing, it also lacks specificity. For those interested in trading PBR stock options, it's not enough to have a thesis regarding the magnitude component or the y-axis of the price chart. Rather, the targeted move must also materialize within the specified time element (x-axis) due to options expiring.
In other words, options traders live in a world of probabilities, which incentivizes statistical analysis. At first glance, this exercise seems simple enough: merely take the frequency of the desired outcome divided by the total number of events in the target dataset. However, this approach only calculates the derivative probability or the outcome odds over the dataset's entire distribution. What traders are looking for is the conditional probability — outcome odds over a specific subset of the data.
Derivative probabilities are akin to the advice that educators often give: because the <a href="https://thecollegesolution.com/the-odds-of-a-full-ride-athletic-scholarship/">odds</a> of receiving an athletic scholarship are so low, it's best to focus on academic scholarship opportunities. But if you're a phenomenal football player, your conditional odds of receiving a full ride based on your athletic abilities may be exponentially greater than the aggregate odds.
That's essentially the point about PBR stock. Based on its price action and past analogs, PBR may be poised to perform better than it usually does. But to calculate the odds, we must first convert past price data into a unified language, which is where market breadth comes in. As sequences of accumulative and distributive sessions, market breadth is effectively binary and thus enables categorization and quantification. Ultimately, these attributes empower probabilistic analysis.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25145642/PBR-stock-10wk-forecast-1024x576.jpg" alt="" class="wp-image-962129" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25145642/PBR-stock-10wk-forecast-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25145642/PBR-stock-10wk-forecast-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25145642/PBR-stock-10wk-forecast-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25145642/PBR-stock-10wk-forecast.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
Currently, PBR stock is printing a "4-6-U" sequence: four up weeks, six down weeks, with a net positive trajectory across the 10-week period. Admittedly, the conversion of past pricing data into a binary code compresses the underlying magnitude component. However, the key benefit of this compression is the categorization of price action as discrete behavioral states. These states reflect past analogs, which can be studied to determine the likelihood of transition from one state to another.
From past empirical data, we can objectively determine that when the 4-6-U sequence flashes, the following week's price action results in upside 68.75% of the time, with a median return of 2.43%. Should the bulls maintain control of the market for a second week, the projected upside return is 2.58%.
<h2 class="wp-block-heading">A Daring But Enticing Call Spread To Consider</h2>
Based on the market intelligence above, aggressive speculators may consider the 12/13 bull call spread expiring July 18. This transaction involves buying the $12 call and simultaneously selling the $13 call, for a net debit paid of $48 (the most that can be lost in the trade). Should PBR stock rise through the short strike price ($13) at expiration, the maximum reward is $52, a payout of over 108%.
For those who are super-aggressive, the 12.50/13 bull spread (also expiring on July 18) is available. Here, the net debit is lower at $17 and the max reward is $33, translating to a payout of over 194%. However, the breakeven price for this trade is $12.67 as opposed to $12.48 for the 12/13 spread, meaning that the probabilistic risk is also higher.
Still, the common incentive undergirding both trades is the implied shift in sentiment regime of the 4-6-U sequence. As a baseline, the chance that a long position in PBR stock will be profitable over any given week is only 51.82%. Therefore, those already prone to speculation have a statistical incentive to swing the bat.
The opinions and views expressed in this content are those of the individual author and do not necessarily reflect the views of Benzinga. Benzinga is not responsible for the accuracy or reliability of any information provided herein. This content is for informational purposes only and should not be misconstrued as investment advice or a recommendation to buy or sell any security. Readers are asked not to rely on the opinions or information herein, and encouraged to do their own due diligence before making investing decisions.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/options/25/06/46083803/tjx-stock-upside-shoppers-hunt-discounts">Options Corner: TJX Companies May Be Poised For Upside As Shoppers Hunt For Discounts</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Options

Events

Global

Options Corner: A Tenuous Ceasefire Keeps Petrobras In Play For Opportunistic Traders

WIIM

Flagstar shares are trading lower amid Zohran Mamdani's lead in the Democratic mayoral primary.

<a href="https://investor.lilly.com/news-releases/news-release-details/fda-approves-updated-label-lillys-amyvid-florbetapir-f-18" title="https://investor.lilly.com/news-releases/news-release-details/fda-approves-updated-label-lillys-amyvid-florbetapir-f-18">https://investor.lilly.com/news-releases/news-release-details/fda-approves-updated-label-lillys-amyvid-florbetapir-f-18</a>

Biotech

Ely Lilly Announces The U.S. FDA Approves Updated Label For Its Amyvid To Support Diagnosis Of Alzheimer's Disease In Patients

Macro Economic Events

Market Summary

Economics

ESRT

Benzinga Market Summary: S&P Flat And Oil Rises As Investors Assess Middle East Situation, NY Real Estate Stocks Fall Amid Democratic Mayoral Primary

SRFM

Surf Air Mobility shares are trading lower after the company announced a $27 million registered direct offering at $2.50 per share.

Needham analyst Gerald Pascarelli reiterated the Buy rating on Constellation Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>), lowering the<a href="https://www.benzinga.com/quote/STZ/analyst-ratings" target="_blank" rel="noreferrer noopener"> price forecast from $215 to $195.</a>
Pascarelli predicts Constellation Brands will report a weak start to fiscal year 2026 when it announces first-quarter results on July 1.
The analyst expects beer revenue and margins to fall below the lower end of full-year guidance, which could negatively impact Street estimates.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/management/25/05/45455434/warren-buffett-ditches-bitcoin-linked-nu-holdings-adds-to-constellation-brands-dominos-pizza-pool-corp-stakes" rel="noreferrer noopener">Warren Buffett Ditches Bitcoin-Linked Nu Holdings, Adds To Constellation Brands, Domino&#8217;s Pizza, Pool Corp Stakes</a>
Over the past three months, beer volumes have declined sequentially, Hispanic consumer sentiment hasn&#8217;t improved, and weather has been unfavorable.
Pascarelli&#8217;s beer depletion forecast of -3.0% is 120 bps below the -1.8% consensus.
The analyst has reduced his first-quarter earnings per share estimate to $3.20 and lowered his fiscal year 26 and fiscal year 27 EPS estimates to $12.64 and $13.76, respectively.
Pascarelli&#8217;s price forecast drops to $195, implying a ~20% discount to the company&#8217;s historical average multiple of ~14x.
The analyst notes that beer volume trends weakened since February due to category softness, ongoing consumer challenges, and poor weather in May and early June.
With volumes down over 1% in scanner data, Pascarelli models a 3.0% first quarter depletion decline and 2.0% shipment drop, partially offset by 1.5 points of price. This yields a -0.5% organic sales estimate, 30 bps below consensus.
Increased investment spending, especially in marketing (estimated at 9.5% of sales), and volume pressure contribute to a 38.0% beer margin forecast, notably below the Street&#8217;s 39.8%.
Pascarelli is also 10 points below consensus on wine and spirits revenue, expecting a ~30% organic decline. The Svedka divestiture (~5-point hit) further pressured the company.
Volume deleverage and distributor repayments lead him to model a 70% drop in segment operating income.
The analyst&#8217;s $3.20 EPS forecast is ~5% below consensus at $3.37.
Pascarelli sees that despite a weak start to fiscal year 26, Constellation Brands&#8217; initial beer guidance was conservative enough to allow the company to meet its full-year targets.
The analyst points out that Constellation Brands typically avoids revising guidance in the first quarter. During May and June presentations, management suggested they expected improved trends after the first quarter, helped by easier year-over-year comparisons and a soft category performance last summer.
While management may opt to reiterate current guidance and wait to reassess in July or August, Pascarelli doubts this approach will be well-received, as investors may question the achievability of full-year goals given the sluggish performance in June.
Price Action: STZ shares are trading lower by 1.7% to $161.71 at last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46096528/nasdaq-100-record-highs-rally-historical-performance" target="_blank" rel="noreferrer noopener">Nasdaq 100 Hits Record Highs After 30% Rally: History Suggests It&#8217;s Not Done Yet</a></li>
</ul>
Photo: The Image Party/Shutterstock

Markets

Analyst Ratings

Trading Ideas

Beer Demand Slumps, Margins Squeezed: Why This Analyst Still Likes Constellation

CrowdStrike Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) shares are trading higher Wednesday. Concerns over potential Iranian cyberattacks may have pushed investor interest <a href="https://www.benzinga.com/news/politics/25/06/46088581/federal-reserve-on-alert-amid-potential-iranian-cyberattack-threats-says-jerome-powell-its-a-big-issue">toward cybersecurity stocks.</a>
What To Know: The move follows comments from Federal Reserve Chair Jerome Powell during a congressional hearing, where he acknowledged that the Fed is on high alert for possible retaliation from Iran in the form of cyberattacks. This comes after recent U.S. military strikes on Iranian nuclear sites, which have increased geopolitical tensions and heightened the risk of digital retaliation. 
Powell emphasized that cyber threats remain a major concern, stating that no institution can afford to be complacent because "the bad guys are always getting better."
Past Iranian cyber operations have targeted U.S. financial infrastructure and government agencies are once again warning institutions to be prepared. The financial sector, in particular, is seen as a likely target, making firms like CrowdStrike more central to national and corporate defense strategies.
The rising threat level has drawn attention back to CrowdStrike and its peers, which are viewed as critical providers of advanced digital security in volatile geopolitical environments. A brief investor relations update from CrowdStrike earlier this week also highlighted ongoing expansion in enterprise partnerships.
CRWD Price Action: Crowdstrike shares were up 1.51% at $492.69 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46100531/trump-nato-nvidia-chipmakers-nasdaq-record-high">Tech Stocks Notch New Highs As Chipmakers Power The Rally: What&#8217;s Driving Markets Wednesday?</a></li>
</ul>
Image Via Shutterstock.

CRWD

What's Going On With CrowdStrike Shares Today?

Shares of Nano Labs Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) are pulling back sharply Wednesday afternoon, a day after soaring on news of a major strategic shift towards the BNB cryptocurrency.
What To Know: The China-based Web 3.0 company announced on Tuesday a private placement agreement to raise up to $500 million through convertible senior notes to fund its new &#8220;<a href="https://www.benzinga.com/trading-ideas/movers/25/06/46075770/nano-labs-stock-is-soaring-tuesday-whats-going-on">BNB treasury strategy</a>.&#8221;
The initial announcement sent the stock climbing. Nano Labs revealed its ambitious plan to acquire $1 billion worth of BNB, the native cryptocurrency of the Binance chain, with a long-term goal of holding 5% to 10% of its total circulating supply. 
This move marks a significant expansion of its digital asset holdings, which previously focused on Bitcoin. The convertible notes have a 360-day maturity and an initial conversion price of $20 per ordinary share.
What Else: In a Form 6-K filing with the SEC on Wednesday, Nano Labs provided additional clarity. The company disclosed that the <a href="https://ir.nano.cn/static-files/b6a31ef3-c2ac-422f-b345-f1c405ad90ff">$500 million</a> fundraise may occur in multiple tranches.
An initial closing has already taken place, with the company issuing two notes for a total of 600 Bitcoins, valued at approximately $63.6 million. This brings the company&#8217;s total Bitcoin holdings to 1,000. The filing also stipulated that note repayments are to be made in Bitcoin.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, NA shares are trading lower by 20.3% to $11.83 Wednesday afternoon. NA has a 52-week high of $31.48 and a 52-week low of $2.75.
Read Also: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46098980/exclusive-bitcoin-is-hives-war-chest-who-needs-bankers">EXCLUSIVE: Bitcoin Is HIVE&#8217;s War Chest &#8211; Who Needs Bankers?</a>
<h2 class="wp-block-heading">How To Buy NA Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Nano Labs&#8217; case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Image: Shutterstock

Nano Labs Stock Is Getting Hammered Wednesday: What's Going On?

PONY

PONY stock has given up its prior gain. Pony AI shares were trading higher after the company announced it has been added to the Nasdaq Golden Dragon China Index.

COIN

Coinbase shares are trading higher after Bernstein maintained an Outperform rating and raised its price target from $310 to $510.

The <a href="https://www.benzinga.com/topic/fda-0">U.S. Food and Drug Administration</a> (FDA) is aware that Medtronic Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) and its subsidiary, Given Imaging Inc., have issued two letters to affected customers recommending that certain Bravo CF Capsule Delivery Devices be removed from where they are used and sold.
What Happened: Earlier in June, Medtronic <a target="_blank" href="https://www.fda.gov/medical-devices/medical-device-recalls/early-alert-esophageal-ph-monitoring-capsule-issue-medtronic" rel="noreferrer noopener">sent</a> all affected customers an "URGENT: MEDICAL DEVICE RECALL" letter. An updated letter was sent on June 16.
Medtronic on Tuesday stated that the capsule may not attach to the patient's esophagus or detach from the delivery device as intended due to a misapplication of the adhesive during manufacturing the Bravo CF capsule delivery device.
Risks associated with this issue include patient aspiration/inhalation, perforation of the esophagus, airway obstruction, hemorrhage/blood loss/bleeding, laceration of the esophagus, a delay in diagnosis, and foreign bodies remaining in the patient.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45932090/limited-impact-on-intuitive-surgical-from-reprocessed-robotic-instruments-analyst" rel="noreferrer noopener">Limited Impact On Intuitive Surgical From Reprocessed Robotic Instruments: Analyst</a>
Why It Matters: Medtronic has reported 33 serious injuries and no deaths associated with this issue.
The Bravo system is designed to place and attach a pH monitoring capsule to the esophagus, recording pH data to assist a physician in diagnosing clinical gastroesophageal reflux.
The Bravo system involves placing a pH capsule against the mucosal wall of the esophagus, simultaneously measuring pH, and transmitting the data to a recorder attached to the patient's waist.
The patient interacts with the recorder to indicate symptoms, allowing the physician to compare the patients' symptoms to the occurrence of the reflux episodes.
Additionally, on Monday, the FDA <a target="_blank" href="https://www.fda.gov/medical-devices/medical-device-recalls/medical-procedure-kits-correction-medline-industries-lp-issues-correction-medline-procedure-kits" rel="noreferrer noopener">said</a> that Medtronic&#8217;s subsidiary, Medline Industries, LP, sent all affected customers an Immediate Action Required Medical Device Recall notice in February.
Medline Industries LP is correcting certain lots of their medical procedure kits containing recalled Medtronic Aortic Root Cannulas due to the potential for excess material in the male luer. 
Medline is providing a sticker to attach to the procedure kits, notifying the user not to use the aortic root cannula within the procedure kit and to use an aortic root cannula from another supplier.
The use of the affected products may cause serious adverse health consequences, including procedure delay, neurological deficits/stroke (reversable and irreversible), and death. &nbsp;&nbsp;
&nbsp;At this time, Medline Industries has reported no serious injuries or deaths related to this issue.
Medline medical procedure kits containing Medtronic Aortic Root Cannulas are convenience kits used for various medical procedures.
The Medtronic Aortic Root Cannula in the kit is used for six hours or less during surgery with the heart-and-lung machine (cardiopulmonary bypass). The cannula may also be used to remove air from the major artery (aorta) when a bypass procedure is finished.
Price Action: MDT stock is up 0.3% at $86.36 at the last check on Wednesday
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/06/46098062/paychex-stock-takes-a-hit-as-margin-squeeze-overshadows-outlook" target="_blank" rel="noreferrer noopener">Paychex Stock Takes A Hit As Margin Squeeze Overshadows Outlook</a></li>
</ul>
Photo: Shutterstock

Large Cap

Health Care

FDA Sounds Alarm After 33 Injuries Tied To Medtronic Device Malfunction

It's already been an eventful week for U.S. markets, with tensions in the Middle East bubbling and then calming down following a <a href="https://www.benzinga.com/news/politics/25/06/46042703/iran-calls-us-bombing-of-nuclear-sites-very-very-dangerous-for-everybody">weekend of bombardment.</a> But despite the uncertainty regarding a potential ceasefire, the stock and commodities markets shrugged it off with the NASDAQ 100 finally notching a new all-time high and oil prices dipping back under $66 per barrel.
Markets are not out of the woods yet, as consumer sentiment continues to be shaky and the Fed remains on hold awaiting more economic data on the impact of tariffs. But the trend toward new all-time highs appears strong and retail traders are back to being bullish.
<h2 class="wp-block-heading">July 4th Sale: Save Up To $1,200 On Benzinga Pro</h2>
Your current setup is costing you money, whether it's free or expensive. Scattered tools mean missed opportunities. Consolidate everything into one powerful platform that actually works together. Stop missing opportunities. Sign up <a href="https://www.benzinga.com/pro/register/4th-of-july-sale/?utm_campaign=bzpro-4th&amp;el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}&amp;utm_adType=SponsorAd&amp;utm_ad=RD062625">HERE</a> for Benzinga Pro at 60% off. 
Each of the five stocks rates highly on Benzinga Edge's Value Score rankings and exhibits technical signals indicating that momentum shifts may be brewing beneath the surface.
<h2 class="wp-block-heading">Costamare Inc.&nbsp;</h2>
Benzinga Edge Value Score: 98.04
Bulk shippers like Costamare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMRE#NYSE">CMRE</a>) have been caught in the Trump administration's tariff tug-of-war, but the decline has been so steep that the stock now appears undervalued. Despite a Q1 2025 earnings beat on both EPS and revenue, CMRE trades at just 3.7 times earnings and 0.5 times sales, and the dividend now yields over 5%.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXepogNA3oub0pkCTAE-Z1tJik259Dyf1zUxOYl00I0O1bb-228WkeiN_0bLeOw-H58rgG6TCAGG648vqj8Vbhxk-BLL23pBWuZ2A1gjIy6pLmgml2JBiLIoJ1dimfcwCPqqFeotng?key=hP5zZ9dGchmBHAd5CwfA1Q" alt="" /></figure>
CMRE spent most of the last 12 months in a prolonged downtrend. The stock peaked at $12.75 in June 2024 before dropping nearly 50%, with frequent false signals when the Relative Strength Index (RSI) tripped the Oversold alarm.&nbsp; But the stock rallied after the market bottom that followed Trump's reciprocal tariff announcement, gaining 10% and finally breaking through the long-term resistance level that had been in place for nearly a year. The RSI anticipated the breakout and actually triggered an Overbought signal twice in May and June, but now that it's back below 70, the new uptrend can continue.
<h2 class="wp-block-heading">Peabody Energy Corp.&nbsp;</h2>
Benzinga Edge Value Score: 98.08
Coal miners have also struggled in 2025 despite reassurances from the Trump administration. Small caps like Peabody (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTU#NYSE">BTU</a>) ($1.54 billion market cap) have been trending downward since Election Day. But BTU now trades at just 5 times forward earnings and 0.4 times sales, but its terrible start to 2025 (down 40% year-to-date) could be about to change. 
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXfX88YZ1zVqX8S0ODVvGaIsbqlVMPbJVvQwyRuFdNFUxuE1_GwHNMv2wqPlCrEFp1AtWvhErPuUtfKjbjMpBBfPjkFcmx5Rj_5vepvdoj2-354hA0QxQC-bDTycZw4Om8r0T3JI?key=hP5zZ9dGchmBHAd5CwfA1Q" alt="" /></figure>
Peabody's stock didn't experience a lengthy drawdown like CMRE, but the decline's brevity didn't mask its fierceness. The stock dropped more than 60% from Election Day to Easter, trading in a tight range with multiple failed attempts to breach support and resistance levels. The downtrend finally broke in April, and although the stock hasn't exactly gone parabolic, the breakout was confirmed by a bullish MACD crossover in May. The climb back to new highs might be a slow one, but BTU has an attractive valuation and a chart signaling the momentum has turned. It also still has a short interest of over 17%, which could further fuel any rallies in the coming days or weeks.
<h2 class="wp-block-heading">Hello Group Inc.&nbsp;</h2>
Benzinga Edge Value Score: 97.31
Hello Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOMO#NASDAQ">MOMO</a>) was a meme stock before there were meme stocks; its chart from 2017 and 2018 is enough to give even seasoned investors vertigo. But those days are long gone, and the stock has spent years trying to break out of a fortress-like resistance level. However, now that the stock trades at just eight times earnings and 0.7 times sales, investors are giving it a second look, and that resistance level has finally been broken.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXeqIMYt2D-5FPmnHZ_uycJYfVUM6YpwpfWPBVAv55Si8bSEmdGYFnbMmICjgpqFm7N9CyeylBor1Kg7qXSU3iNJvqpHfMR-rpui8p9nzZl0jTmylGY-Px19kB0_Og03AKpJcVT1Tw?key=hP5zZ9dGchmBHAd5CwfA1Q" alt="" /></figure>
Talk about lengthy range-bound trading, Hello Group has traded between $5 and $8 since September 2023, and has failed multiple attempts to break through the resistance level above the $8 mark. But the MACD is showing outsized bullish momentum compared to previous quarters. The share price finally crested $8.15 for the first time in nearly two years. Volatility is increasing (did you expect something different with the ticker MOMO?), but if the old resistance level becomes support, this stock might not be done posting explosive gains in 2025.
<h2 class="wp-block-heading">Hamilton Insurance Group Ltd.&nbsp;</h2>
Benzinga Edge Value Score: 95.46
Hamilton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HG#NYSE">HG</a>), a small-cap insurer based in Bermuda, has a market capitalization of $2.15 billion and annual sales of $2.3 billion. Strong earnings and guidance raises have fueled the stock's recent upward move, as the company handily beat EPS (0.48 per share vs. the expected 0.04) and revenue estimates ($843 million vs. the expected $498 million). But despite this massive beat, the stock still trades at just 5 times forward earnings and 0.9 times sales. 
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXfpPbi5r2etuPt1EIIZowVx3H4uW2WOWxCi8fU0PFtBA9UG1fwnOpVci1FucqSDMPc-9yfRD9qvdOuBlp5tNDwJNuNnNYYGA5vn9utbV2AX4LP6GcvvbkMU4bmrkkqkBeTFPTSzPw?key=hP5zZ9dGchmBHAd5CwfA1Q" alt="" /></figure>
Above is a chart showing an undervalued company poised to build a new bull market. The stock price has been trading above both the 50-day and 200-day MAs, with the 50-day MA acting as support since mid-2024. Trump's tariffs briefly interrupted this trend, but the price quickly rose back above both MAs and appears to be balancing along the 50-day once again. The RSI is also back under 60 after a brief venture into Overbought territory, so another bounce off the 50-day would likely have strong upside momentum.
<h2 class="wp-block-heading">Tri-Pointe Homes Inc.&nbsp;</h2>
Benzinga Edge Value Score: 95.14
Investing in homebuilders is a dicey proposition at the moment, considering the headwinds facing the construction industry. However, Tri-Pointe's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPH#NYSE">TPH</a>) surprisingly strong Q1 2025 earnings indicate a resilient company capable of weathering economic turbulence. TPH posted EPS figures of $0.70 per share, easily exceeding the $0.45 per share estimate. The April report also triggered a momentum shift in the stock, which currently trades at just 8.9 times forward earnings and 0.65 times sales.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXeDNgKBM88C12hDZmnsVLwopEb16MbGlyPNMOyDcylqxqTQWvF_bLukcvCnDXwF6O4NXh1gpzT4GWBJ6m31JGOwgYSg4-Ao8sf8ytTSwfcNKN4QsfphbXe46Qnj6CAbuq54dapFhQ?key=hP5zZ9dGchmBHAd5CwfA1Q" alt="" /></figure>
Like most homebuilders, TPH's shares couldn't shake downward momentum as high mortgage rates kept the housing market frozen. Housing is still struggling to gain traction (highlighted by this week's <a href="https://www.benzinga.com/news/macro-notification/25/06/46070420/us-home-sales-sink-to-slowest-may-since-2009-as-mortgage-rates-and-record-prices-keep-buyers-on-the-sidelines">poor report</a> in new home sales), but TPH has finally broken its downtrend, and momentum is slowly consolidating at a new support level. The RSI has been trending upward in unison with the stock price, giving more weight to the momentum shift. And with the RSI sitting at 57, the upswing likely has more room to run.
Editorial content from our expert contributors is intended to be information for the general public and not individualized investment advice. Editors/contributors are presenting their individual opinions and strategies, which are neither expressly nor impliedly approved or endorsed by Benzinga.
Photo: Shutterstock

Small Cap

Opinion

CMRE

MOMO

5 Undervalued Small Caps Showing Signs Of Breaking Out

FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) shares are moving lower Wednesday after the company issued soft guidance for the first quarter. Multiple analysts also cut price targets following the company&#8217;s <a href="https://www.benzinga.com/markets/earnings/25/06/46083842/fedex-q4-earnings-revenue-eps-beat-estimates-shares-slide-on-soft-guidance">fourth-quarter results</a>.
Q4 Details: FedEx reported adjusted earnings per share of $6.07, beating the consensus estimate of $5.87. In addition, the company reported sales of $22.20 billion, beating the consensus estimate of $21.83 billion.
Q1 Outlook: FedEx sees adjusted earnings per share of $3.40 to $4.00, versus the consensus estimate of $4.15.
Competitor United Parcel Service Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) may also be trading lower in sympathy with FedEx, as investors view the soft guidance as a potential sign of broader industry challenges. UPS isn&#8217;t due to report earnings until next month.
Analyst Changes: Following the earnings report, multiple analysts issued <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/quote/FDX/analyst-ratings&amp;ved=2ahUKEwjAlaWEhY2OAxUJFFkFHY2EFcMQFnoECBgQAQ&amp;usg=AOvVaw0NWQwtY68qb5CbFcDU6hyi">price target adjustments</a>.
<ul class="wp-block-list">
<li>Citigroup analyst Ariel Rosa maintained a Buy rating on FedEx and lowered the price target from&nbsp;$267&nbsp;to&nbsp;$259.</li>
<li>TD Cowen analyst Jason Seidl maintained a Buy rating on FedEx and lowered the price target from&nbsp;$310&nbsp;to&nbsp;$269.</li>
<li>Stifel analyst J. Bruce Chan maintained a Buy rating on FedEx and lowered the price target from&nbsp;$329&nbsp;to&nbsp;$315.</li>
<li>Susquehanna analyst Bascome Majors maintained a Positive rating on FedEx and raised the price target from&nbsp;$290&nbsp;to&nbsp;$295.</li>
<li>UBS analyst Thomas Wadewitz maintained a Buy rating on FedEx and lowered the price target from&nbsp;$311&nbsp;to&nbsp;$297.</li>
</ul>
See Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46099726/super-micro-computer-smci-stock-is-surging-today-whats-going-on">Super Micro Computer (SMCI) Stock Is Surging Today: What&#8217;s Going On?</a>
FDX Price Action: At the time of publication, FedEx Stock was down 3.41% at $221.70, according to data from <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/pro/&amp;ved=2ahUKEwjv3bfFho2OAxWnEFkFHankK0oQFnoECCkQAQ&amp;usg=AOvVaw0xIsPvjIcIIsWev01-6zR2">Benzinga Pro</a>.
Image via Shutterstock.

FedEx Stock Is Trading Lower Wednesday: What's Going On?

<a href="https://www.sec.gov/Archives/edgar/data/1946703/000121390025057745/ea0246681-f1_webuy.htm">https://www.sec.gov/Archives/edgar/data/1946703/000121390025057745/ea0246681-f1_webuy.htm</a>

Offerings

WBUY

Webuy Global Files For Offering Of 1M Class A Ordinary Shares And/Or Pre-Funded Warrants To Purchase Class A Ordinary Shares

Once a symbol of financial catastrophe, subprime consumers are now showing signs of resilience and spending power that defy economic uncertainties, according to Goldman Sachs, with the bank highlighting several investment opportunities tied to <a href="https://www.benzinga.com/analyst-ratings/analyst-color">the lower-income group. </a>
In a note issued Wednesday, Goldman Sachs analysts led by George K. Tong said U.S. subprime consumers—typically defined as individuals with credit scores below 660—are holding up better than expected despite economic headwinds such as tariffs, inflation and high interest rates.
<h3 class="wp-block-heading">US Subprime Consumers Are Stronger Than You Think</h3>
"Our call is that subprime consumers are, and will remain, resilient, with positive spending growth and improving delinquency trends despite economic uncertainty," Tong said.
Consumer wealth in the bottom income quintile rose 7% year-over-year through May 2025. The labor market remains reasonably healthy, with unemployment at 4.2% in May, while debt service payments as a share of disposable income came in at 11.3%, below the 45-year average of 11.9%.
Household debt stood at 61% of nominal GDP in 2024, the lowest level since late 1999 and significantly under the 20-year average of 70%, suggesting consumers remain financially unburdened.
Goldman said subprime borrowers are actively adjusting their financial behavior by shifting away from discretionary and high-cost items, instead prioritizing essential purchases such as groceries, household goods and lower-cost alternatives. 
This disciplined approach to spending reflects a prudent response to economic uncertainty—not distress.
<h3 class="wp-block-heading">Subprime Credit Metrics Show Positive Signs</h3>
Recent data shows a broad improvement in credit health across cards, auto loans and personal loans, suggesting that subprime consumers are stabilizing their financial positions. 
Thirty-plus day card delinquencies among lower-income borrowers fell 0.23% year-over-year in the first quarter of 2025 to 4.5%, marking a key reversal after a prolonged period of rising late payments. 
Deep subprime 60-plus day card delinquencies declined to 25.46% in May 2025, down from 27.42% a year earlier, the first sustained drop since late 2022.
In the auto segment, 60-plus day delinquencies among deep subprime borrowers slipped to 7.75% in May, now falling below the five-year average of 7.80%. This marks a turning point after nearly two years of worsening trends. 
Similarly, deep subprime personal loan delinquencies fell from 15.27% to 14.25% in May, extending the string of year-over-year improvements that began in mid-2024. 
Mortgages remain the only category showing slight deterioration, with deep subprime 90-plus day delinquencies rising to 12.92% in May, up from 11.59% a year ago, slightly above the five-year average of 12.88%. 
Yet, the investment bank notes that overall mortgage delinquency remains exceptionally low at just 0.7% of outstanding balances, reflecting the relative health of the broader housing market.
<h3 class="wp-block-heading">Subprime Crisis? Not This Time – 8 Stocks To Watch</h3>
Goldman Sachs recommends eight stocks across various sectors that are well-positioned to benefit from this subprime resurgence:
<ol class="wp-block-list">
<li>Fair Isaac Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NASDAQ">FICO</a>) – Buy-rated, $2,244 price target With improving delinquency trends, FICO could see a pickup in credit originations and score inquiries.</li>
<li>Dollar Tree Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) – Buy-rated, $94 PT Budget-focused consumers are helping drive growth, especially as DLTR boosts operational efficiency.</li>
<li>Philip Morris International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>) – Buy-rated, $190 PT Steady demand for non-discretionary tobacco and ZYN products fuels growth, even in low-income segments.</li>
<li>Monster Beverage Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>) – Buy-rated, $72 PT Energy drinks remain an affordable indulgence for subprime consumers, supporting revenue and margin expansion.</li>
<li>Affirm Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) – Buy-rated, $58 PT As a leading Buy Now, Pay Later provider, AFRM is gaining from better credit and growing demand.</li>
<li>Block Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>) – Buy-rated, $57 PT Block's Cash App and lending business is rebounding, supported by subprime borrower stability.</li>
<li>Capital One Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) – Buy-rated, $242 PT Credit card and auto segments are seeing improving delinquency trends and potential reserve releases.</li>
<li>Synchrony Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>) – Buy-rated, $70 PT With 28% of loans to subprime consumers, SYF is poised to benefit from improving net charge-off and delinquency data.</li>
</ol>
Read now:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46096528/nasdaq-100-record-highs-rally-historical-performance">Nasdaq 100 Hits Record Highs After 30% Rally: History Suggests It&#8217;s Not Done Yet</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Econ #s

AFRM

DLTR

FICO

MNST

Subprime Was A Trainwreck In 2008―Now It's A Sweet Spot, Says Goldman Sachs

Molson Coors Beverage Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) is quiet on Wednesday. After <a href="https://www.benzinga.com/content/46043294/these-3-consumer-staple-giants-are-oversold-and-set-to-skyrocket">a long downtrend</a>, the shares have consolidated over the past few days and found support around the $48 level.
They are also very oversold and may be starting to reverse. This is why it is our Stock of the Day.
Stocks that are oversold and drop to support tend to rebound and rally. As you can see on the chart, this happened when Molson found support around the $52.50 level in January and early May.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="591" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25151948/TAP-1024x591.png" alt="" class="wp-image-962168" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25151948/TAP-1024x591.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25151948/TAP-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25151948/TAP-768x443.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25151948/TAP.png 1410w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Oversold refers to a stock's momentum. Most of the time, a stock is within its typical trading range. If aggressive and emotional sellers push the price below this range, traders will say the stock is oversold.
Read Also: <a href="https://www.benzinga.com/markets/tech/25/06/46096528/nasdaq-100-record-highs-rally-historical-performance">Nasdaq 100 Hits Record Highs After 30% Rally: History Suggests It&#8217;s Not Done Yet</a>
This is an important dynamic.
It will draw buyers into the market. Many strategies are based on the concept of reversion to the mean, and these buyers will be anticipating a move higher. Their buying could put upward pressure on Molson.
The stock is also at a support level.
Support is a level or narrow price range with a large amount of buying interest. If a stock is trending lower, it is due to the lack of demand or a limited number of buyers. But at support levels, there is enough demand to absorb the supply.
This is why selloffs end or pause at support. &nbsp;
Molson has found support at around $48.30. This level was also support in August.
Some of the traders who sold their shares then came to believe they had made a mistake when the price headed higher. Some vowed to repurchase their shares at their selling prices if they could ever do so.
So, when the stock recently dropped back to this price, these remorseful sellers placed buy orders. The large concentration of these orders caused support to form at the level again.
This combination of being at a level where there is a large amount of buy interest in addition to being oversold could be a bullish setup. Molson may be about to rally.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/46094069/iran-breaks-silence-says-nuclear-facilities-badly-damaged-by-us-strikes">Iran Breaks Silence, Says Nuclear Facilities &#8216;Badly Damaged&#8217; By US Strikes</a></li>
</ul>
Photo: Shutterstock

Technicals

Stock Of the Day: Will Molson Coors Finally Reverse?

<a href="https://www.cnbc.com/2025/06/25/southwest-airport-lounges-europe-flights-ceo-bob-jordan.html">https://www.cnbc.com/2025/06/25/southwest-airport-lounges-europe-flights-ceo-bob-jordan.html</a>

'Southwest Airport Lounges? CEO Says Carrier Is Open To Even More High-End Changes'- CNBC

Bitcoin Cash (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/bch/usd">BCH</a>) is soaring higher during midday trading on Wednesday, with its price climbing around 6.30% to $482.62. Here&#8217;s what investors <a href="https://www.benzinga.com/crypto">need to know</a>.
What To Know: The upward momentum for BCH Wednesday is not happening in isolation. The wider crypto market is showing renewed strength, fueled by optimism over a potential Federal Reserve rate cut, supportive legislative news and sustained institutional buying.
During his <a href="https://www.benzinga.com/markets/equities/25/06/46100531/trump-nato-nvidia-chipmakers-nasdaq-record-high">second day</a> of congressional testimony, Federal Reserve Chair Jerome Powell linked potential interest rate cuts to evolving trade conditions. While offering no specific timeline, he suggested that future trade agreements could create the flexibility needed to lower rates.
Read Also: <a href="https://www.benzinga.com/money/how-to-buy-bitcoin-cash">How To Buy Bitcoin Cash</a>
Major assets like Solana also posted <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46091840/bitcoin-ethereum-xrp-dogecoin-hold-gains">strong gains</a> of 6%, while market leader Bitcoin traded 1.2% higher, surpassing the $107,000 mark. The collective rally across tech and crypto Wednesday likely indicates renewed investor confidence as positive macroeconomic and industry-specific developments drive assets higher across the board.
What Else: For investors, Bitcoin Cash is a cryptocurrency that spun off from the original Bitcoin in 2017. It was created to serve as a more efficient system for everyday transactions.
By increasing the block size of its blockchain, Bitcoin Cash aims to process payments faster and with lower fees than its predecessor, positioning itself as a form of &#8220;peer-to-peer electronic cash.&#8221;
Read Also: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46101110/bitcoin-senator-cynthia-lummis-lauds-white-houses-real-enthusiasm-for-crypto-legislation">&#8216;Bitcoin Senator&#8217; Cynthia Lummis Lauds White House&#8217;s &#8216;Real Enthusiasm&#8217; For Crypto Legislation</a>

$BCH

What's Going On With Bitcoin Cash Wednesday?

CoreWeave, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) shares are trading lower on Wednesday. HC Wainwright &amp; Co. initiated coverage on the stock with<a href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/06/46097418/coreweave-ipo-was-fantastic-entry-point-but-stock-now-a-little-overheated"> a Neutral rating</a>.
What To Know: Despite several positive points, HC Wainwright &amp; Co. analyst Kevin Dede said on Wednesday that the stock may need a "minute to breathe" after soaring fivefold, compared to a 25% gain in the Nasdaq over the same period.
Some of the analyst's bullish points include CoreWeave's early deployment of Nvidia's GB200 chips, giving it a first-mover edge in AI infrastructure. The company has also secured long-term contracts with major customers like OpenAI, Microsoft and Meta, offering strong revenue visibility.
The analyst added that CoreWeave is positioned to benefit from a fast-growing AI and software market, which could boost performance and help retain customers.
On the other hand, Dede flagged several risks, including CoreWeave's heavy capital needs. Furthermore, the company has outlined a $20 to $23 billion capex plan this year, which may require taking on more debt or selling additional stock.
Additionally, the analyst pointed to execution risks tied to CoreWeave's data center partners, noting that delays or supply chain issues could make it harder for the company to meet customer obligations.
See Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46101268/the-metals-company-tmc-stock-is-climbing-wednesday-whats-going-on">The Metals Company (TMC) Stock Is Climbing Wednesday: What&#8217;s Going On?</a>
CRWV Price Action: At the time of publication, CoreWeave stock was down 6.57% at $161.32, according to data from <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/pro/&amp;ved=2ahUKEwj_6pDhk42OAxWjhIkEHaySERAQFnoECCQQAQ&amp;usg=AOvVaw0xIsPvjIcIIsWev01-6zR2">Benzinga Pro</a>.
Image via Shutterstock.

CRWV

CoreWeave Stock Is Moving Lower Wednesday: What's Going On?

Personalized medicine, which involves tailoring treatment to a patient&#8217;s unique disease profile, is widely regarded as the holy grail of medicine. However, the current implementation of this approach faces significant hurdles.
Bank of America Securities (BofA) highlights that the precision medicine approach is currently <a target="_blank" href="https://www.benzinga.com/topic/artificial-intelligence" rel="noreferrer noopener">cost, labor, and time-intensive</a>.
Analysts Alec Stranahan and Michael Ryskin specifically point out that the substantial amount of manual work involved in processing complex biological data and making treatment decisions leads to considerable delays.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/06/45820489/goldman-sachs-bullish-on-branded-drug-upside-at-teva-what-about-viatris" rel="noreferrer noopener">Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?</a>
Beyond the practical challenges, precision medicine also grapples with data validation issues. Given the infinitely complex nature of biology and the huge number of interactions between biological systems, researchers often run into issues with validating the impact of genes/pathways associated with disease progression/response to treatment.
Despite these inherent challenges, the integration of Artificial Intelligence (AI) and Machine Learning (ML) is widely recognized as a pivotal enabler for advancing precision medicine.
Consequently, a number of companies are actively leveraging these technologies to innovate within the precision medicine landscape, striving to make tailored treatments more accessible, efficient, and effective.
These companies include Tempus AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), Guardant Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>), Exact Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), NeoGenomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>), Quest Diagnostics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>), and LabCorp Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>), each employing AI in unique ways to enhance diagnostics, therapy selection, and overall patient care across the care continuum.
<h2 class="wp-block-heading">Tempus AI</h2>
BofA analyst says Tempus AI perfectly fits the theme of <a target="_blank" href="https://www.benzinga.com/news/movers-shakers/25/06/45726456/tempus-ai-stock-is-surging-today-what-investors-are-watching" rel="noreferrer noopener">AI in precision medicine</a>.
Like most MDx companies, Tempus AI has built its business off an industry-leading database of clinico-genomic data. Tempus leverages this data by training AI/ML algorithms to parse through the data and detect patterns and anomalies.&nbsp;&nbsp;
BofA reiterates a Neutral rating for Tempus AI, given its already premium valuation. The analyst remains constructive on the business and key markets. However, due to peer group expansion, BofA raised its price <a target="_blank" href="https://www.benzinga.com/quote/TEM/analyst-ratings" rel="noreferrer noopener">forecast from $68 to $70</a>.
<h2 class="wp-block-heading">Guardant Health</h2>
Guardant Health was an early mover in the liquid biopsy cancer testing/therapy selection market with their <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/06/45756387/why-is-cancer-diagnostic-guardant-health-stock-trading-higher-on-tuesday" rel="noreferrer noopener">Guardant 360 (G360) test</a>.
Guardant Health has a clear goal to build upon its G360 test (therapy selection) and expand across the care continuum, thus allowing it to participate in a patient&#8217;s receiving precision medicine at all stages post-cancer diagnosis.
Guardant Health has its business built on the algorithms that it runs.
BofA <a target="_blank" href="https://www.benzinga.com/quote/GH/analyst-ratings" rel="noreferrer noopener">maintains a Buy rating</a> on Guardant Health, given its leading position, strong growth profile, and upcoming catalyst path for new products.
<h2 class="wp-block-heading">Exact Sciences</h2>
BofA analysts say Exact Sciences Corp. has expanded to offer services <a href="https://www.benzinga.com/general/health-care/25/05/45165534/cancer-diagnostic-firm-exact-sciences-ceo-says-strong-q1-paves-way-for-transformative-2025-lifts-annual-guidance" target="_blank" rel="noreferrer noopener">across the care continuum</a>.
While Exact Sciences started screening for colorectal cancer specifically, their focus has been steered towards all indications and across the treatment paradigm.
Exact Sciences&#8217; legacy Cologuard test / early detection doesn&#8217;t necessarily &#8220;fit&#8221; the precision medicine theme; however, everything Exact has done since is &#8220;precision medicine / AI-aligned,&#8221; BofA added in its investor note on Wednesday.
Given its strong financial profile and near-term catalyst path, the analyst maintains a <a target="_blank" href="https://www.benzinga.com/quote/EXAS/analyst-ratings" rel="noreferrer noopener">Buy rating on Exact Sciences</a>.
<h2 class="wp-block-heading">NeoGenomics</h2>
NeoGenomics has been known as a traditional reference lab offering many hotspot tests. However, by adding the PanTracer testing family and data services offering, NeoGenomics leverages the numerous hotspot data points and can build those into a more robust AI algorithm to inform the more modern therapy selection tests.
The dataset/algorithm and 500+ tests create a flywheel where the tests that are sold generate information. The information informs the algorithm, eventually leading to more accurate algorithms, which help market the tests… bring you back to more tests.
BofA <a target="_blank" href="https://www.benzinga.com/quote/NEO/analyst-ratings" rel="noreferrer noopener">maintains a Neutral rating</a> on NeoGenomics given near-term headwinds and more limited upside versus its prior trajectory.
<h2 class="wp-block-heading">Quest Diagnostics</h2>
Quest Diagnostics is showing trends toward AI in precision medicine with <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44929366/quest-diagnostics-revenue-rebound-strategic-moves-fuel-outlook-confidence" rel="noreferrer noopener">Haystack and PathAI Quest</a>.
While not traditionally considered a &#8220;leader&#8221; in AI/precision medicine, Quest Diagnostics has shown progress toward becoming a company to watch.
At DGX&#8217;s 2025 Investor Day, management discussed innovations in lab diagnostics, including the adoption of AI and automation. Given Quest Diagnostics&#8217; strong, steady performance and lower exposure to macro/policy overhangs, the analyst <a target="_blank" href="https://www.benzinga.com/quote/DGX/analyst-ratings" rel="noreferrer noopener">maintains a Buy rating</a>.
<h2 class="wp-block-heading">LabCorp</h2>
LabCorp Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) aims to be a notable player in AI precision medicine. Although LabCorp is known as a traditional reference lab, with trends toward AI and precision medicine, LH has shown signs of <a target="_blank" href="https://www.benzinga.com/25/02/43539754/labcorp-reports-q4-earnings-beat-and-expects-strong-2025-growth-analyst-reiterates-outperform-on-stable-2025-outlook" rel="noreferrer noopener">jumping on the bandwagon</a>.
While LabCorp already offers NGS tests, there appears to be a clear trend and focus towards advancing its AI/precision medicine portfolio.
BofA <a target="_blank" href="https://www.benzinga.com/quote/LH/analyst-ratings" rel="noreferrer noopener">maintains a Buy rating</a> on LabCorp, given strong and steady performance and lower exposure to macro/policy overhangs.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/06/46100456/tesla-robotaxi-scaling-growth-will-be-slow-in-near-term-goldman-sachs" target="_blank" rel="noreferrer noopener">Tesla Robotaxi Scaling Growth Will Be Slow In Near Term: Goldman Sachs</a></li>
</ul>
Photo by Piotr Swat via Shutterstock

EXAS

Laboratory Corporation Of America Holdings

Could Personalized Medicine Be Your Portfolio's Next Big Winner? Find Out

Press Releases

Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly

Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

Earnings

Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025

Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025

Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under  Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Arcellx

Alvotech

Apogee Therapeutics

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

ImmunityBio

Immunovant

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

Kymera Therapeutics

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Metsera

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Vericel

Veracyte

Viking Therapeutics

Stifel

Citizens Capital Markets

Jefferies

HC Wainwright & Co.

JMP Securities

다음은 지난주 큰 폭의 상승세를 보인 11개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요?
<ol>
<li>퀀텀스케이프(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>)의 주가는 회사가 폭스바겐(Volkswagen)의 배터리 회사인 파워코(PowerCo)와 <a href="https://www.benzinga.com//node/39727990" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">전고체 배터리 산업화</a> 계약을 체결했다고 발표한 후 64.34% 급등했다.</li>
<li>랜티우스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>)의 주가는 전문 <a href="https://www.benzinga.com//node/39717130" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">진단 방사성 의약품</a>에 대한 지불 개선을 위한 CMS 제안 이후 55.93% 급등했다.</li>
<li>선런(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>)의 주가는 37.59% 상승했다. 최근 CPI 데이터에 따라 더 넓은 산업 분야의 기업 주가가 상승했기 때문이다.</li>
<li>키메라 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>)의 주가는 화농한선염과 아토피성 피부염에 대한 임상 2상을 확대해 <a href="https://www.benzinga.com//node/39675035" target="_blank" rel="noreferrer noopener">안전성 및 유효성</a>에 대한 중간 검토를 거쳐 중추적 연구로 보다 신속하게 진행하겠다는 의사를 밝힌 뒤 37.38% 상승했다.</li>
<li>아포지 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APGE#NASDAQ">APGE</a>)의 주식은 35.68% 급등했다.</li>
<li>조비 항공(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>)은 회사가 <a href="https://www.benzinga.com//node/39733461" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">물을 유일한 부산물</a>로 사용하여 523마일을 수소 전기 항공 택시 시연차로 성공적으로 비행했다고 발표한 후 주가는 29.10% 상승했다.</li>
<li>크리네틱스 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNX#NASDAQ">CRNX</a>)은 JP모건이 <a href="https://www.benzinga.com/quote/crnx/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">목표 주가를 47달러에서 54달러로</a> 상향 조정한 후 주가는 21.18% 상승했다.</li>
<li>다인 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>)은 JP모건이 주식에 대해 비중확대 등급을 유지하고 <a href="https://www.benzinga.com/quote/DYN/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">목표 주가를 39달러에서 43달러로</a> 높인 후 주가는 19.75% 상승했다.</li>
<li>서밋 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>)의 주식은 지난주 17.24% 급등했다.</li>
<li>플러그 파워(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>)의 주가는 <a href="https://www.benzinga.com/economics/macro-economic-events/24/07/39728268/inflation-slows-more-expected-to-3-in-june-heightens-expectations-for-rate-cuts-t" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">최근 소비자물가지수(CPI) 발표</a> 이후 전기차 관련주가 상승하면서 16.51% 상승했다. 미국 에너지부는 또한 폐쇄되었거나 위험에 처한 11개의 자동차 시설을 전기 자동차와 공급망 제조를 위해 전환하는 데 17억 달러를 투자한다고 발표했다.</li>
<li>샤오펑(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>)의 주식은 15.56% 상승했다. 6월 중국의 수출이 증가한 것을 계기로 중국 관련 주식이 상승했다.</li>
</ol>
기타 읽어볼 만한 기사:
<ul>
<li><a href="https://kr.benzinga.com/news/%eb%a6%ac%eb%b9%84%ec%95%88%ea%b3%bc-%eb%b0%94%ec%9d%b4%eb%91%90%eb%8a%94-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ea%b3%a0-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-11%ea%b0%9c%ec%9d%98-%eb%8c%80/" target="_blank" rel="noopener">리비안과 바이두는 지난주 최고 성과를 보인 11개의 대형주 주식 중 일부 (7월 7일-7월 13일)</a></li>
<li><a href="https://kr.benzinga.com/news/%eb%84%b7%ed%94%8c%eb%a6%ad%ec%8a%a4%ec%99%80-%eb%8d%b8%ed%83%80-%ed%95%ad%ea%b3%b5%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-10/" target="_blank" rel="noopener">넷플릭스와 델타 항공은 지난주 최악의 성과를 보인 10대 대형주 중 일부 (7월 7일-7월 13일)</a></li>
</ul>
Photo Courtesy of QuantumScape
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Crinetics Pharmaceuticals

뉴스

에 대한 최신 뉴스 Crinetics Pharmaceuticals (NASDAQ:CRNX) 주식

월요일, 7월 15, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌